EUCTR2010-019992-30-AT进行中（未招募）1 期
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 405
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males or females, = 18 years of age at the time of signing the informed consent document
- •2. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted
- •3. Able to adhere to the study visit schedule and other protocol requirements
- •4. Diagnosis of chronic plaque psoriasis for at least 12 months prior to Screening
- •5. Have moderate to severe plaque psoriasis at Screening and Baseline as defined by
- •a. PASI score = 12 and
- •b. BSA = 10%, and
- •c. sPGA = 3 (moderate)
- •6. Must be a candidate for phototherapy and/or systemic therapy
- •7. Must be in good health (except for psoriasis) as judged by the Investigator, based on medical history, physical examination, 12-lead ECG, clinical laboratories, and urinalysis
- •8. Must meet the following laboratory criteria
- •a. White blood cell count = 3000/mm3 (= 3.0 x 10^9/L) and < 14,000/mm^3 (< 14 x 10^9/L)
- •b. Platelet count =100,000/µL (= 100 x 10^9/L)
- •c. Serum creatinine = 1.5 mg/dL (= 132.6 µmol/L)
- •d. AST (SGOT) and ALT (SGPT) = 2 x upper limit of normal (ULN)
- •e. Total bilirubin = 2 mg/dL (34 µmol/L)
- •f. Hemoglobin = 9 g/dL (= 5.6 mmol/L)
- •g. Hemoglobin A1c = 9.0 %
- •9. Females of childbearing potential (FCBP)† must have a negative pregnancy test at Screening and Baseline. FCBP who engage in activity in which conception is possible must use contraception while on study medication and for at least 28 days after taking the last dose of study medication with either: 1) one highly effective form (non-oral hormonal, intrauterine device [IUD], tubal ligation, vasectomized partner); or 2) an oral hormonal contraceptive PLUS one additional form of barrier contraception (male or female latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane], diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge with spermicide); or 3) two forms of barrier contraception (male or female latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]) PLUS one of the following (diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge with spermicide).
- •Note: The protocol language regarding contraception has been revised. As this study is fully enrolled, the updated language regarding contraception is included in Section 6.2 (Contraception Education) of this amendment.
- •† The female subject's chosen form of contraception must be effective by
- •the time the female subject is randomized into the study (for example, hormonal contraception should be initiated at least 28 days before randomization).
- •10. Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception (male latex condom or nonlatex condom NOT made out of natural [animal] membrane [e.g., polyurethane]) while on study medication and for at least 28 days after the last dose of study medication.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 364
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 41
排除标准
- •1. Other than psoriasis, history of any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major uncontrolled disease.
- •2. Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study.
- •3. Any condition that confounds the ability to interpret data from the study.
- •4. Pregnant or breast feeding
- •5. History of allergy to any component of the IP
- •6. Hepatitis B surface antigen positive at Screening
- •7. Anti-hepatitis C antibody positive at Screening
- •8. AST (SGOT) and/or ALT (SGPT) > 1.5 X ULN and total bilirubin > ULN and/or
- •albumin < LLN
- •9. Active tuberculosis (TB) or a history of incompletely treated TB
- •10. Clinically significant abnormality on 12-Lead ECG at Screening
- •11. Clinically significant abnormality based upon chest radiograph with at least PA view (radiograph must be taken within 12 weeks prior to Screening or during the Screening visit). An additional lateral view is strongly recommended but not required.
- •12. History of positive human immunodeficiency virus (HIV), or have congenital or
- •acquired immunodeficiency (eg, common variable immunodeficiency disease)
- •13. Active substance abuse or a history of substance abuse within 6 months prior to
- •14. Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks of Screening. Any treatment for such infections must have been completed at least 4 weeks prior to Screening.
- •15. Malignancy or history of malignancy (except for treated [ie, cured] basal cell or
- •squamous cell in situ skin carcinomas and treated [ie, cured] cervical intraepithelial neoplasia [CIN] or carcinoma in situ of the cervix with no evidence of recurrence)
- •16. Psoriasis flare or rebound within 4 weeks prior to Screening
- •17. Evidence of skin conditions that would interfere with clinical assessments
- •18. Topical therapy within 2 weeks of randomization (including but not limited to topical corticosteroids, topical retinoid or vitamin D analog preparations, tacrolimus,
- •pimecrolimus, or anthralin/dithranol). Exceptions: low-potency corticosteroids (Class 6 or 7; please refer to the Investigators’ Manual) will be allowed as background therapy for treatment of the face, axillae, and groin in accordance with the manufacturers’ suggested usage during the course of the study. Subjects with scalp psoriasis will be permitted to use coal tar shampoo and/or salicylic acid scalp preparations on scalp lesions. An unmedicated skin moisturizer (eg, Eucerin®) will be also permitted for body lesions only. Subjects should not use these topical treatments within 24 hours prior to the clinic visit.
- •19. Systemic therapy for psoriasis within 4 weeks prior to randomization (including but not limited to cyclosporine, corticosteroids, methotrexate, oral retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, sulfasalazine, azathioprine, fumaric acid esters)
- •20. Use of phototherapy within 4 weeks prior to randomization (ie, UVB, PUVA)
- •21. Adalimumab, etanercept, infliximab, or certolizumab pegol within 12 weeks prior to randomization
- •22. Alefacept, briakinumab, or ustekinumab within 24 weeks prior to randomization
- •23. Use of any investigational drug within 4 weeks prior to
研究者
相似试验
进行中（未招募）
3 期
A clinical trial to study safety and efficacy of a fixed dose combination of three antidiabetic drugs versus two antidiabetic drugs in patients with type 2 diabetes mellitusCTRI/2021/10/037461Alkem Laboratories Limited
进行中（未招募）
1 期
AVP-786 in the Treatment of Subjects with Agitation Associatedwith Dementia of the Alzheimer’s TypeAgitation Associated with Dementia of the Alzheimer's TypeMedDRA version: 20.0Level: PTClassification code 10001497Term: AgitationSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2017-001339-38-PLOtsuka Pharmaceutical Development & Commercialization, Inc.550
招募中
1 期
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab in high-risk patients with Atrial fibrillation who have been deemed unsuitable for oral antiCoagulation (LILAC)MedDRA version: 20.0Level: PTClassification code: 10003658Term: Atrial fibrillation Class: 100000004849Atrial FibrillationCTIS2023-503224-66-00Anthos Therapeutics Inc.1,963
进行中（未招募）
1 期
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type.Agitation in Patients With Dementia of the Alzheimer's TypeMedDRA version: 20.0Level: PTClassification code: 10012271Term: Dementia Alzheimer's type Class: 100000004852CTIS2023-504991-31-00Otsuka Pharmaceutical Development & Commercialization Inc.750
进行中（未招募）
1 期
A study to assess the efficacy, safety, and tolerability of AVP-786 for the treatment of agitation in patients with dementia of the Alzheimer’s type.Agitation in patients with dementia of the Alzheimer’s typeMedDRA version: 21.1Level: LLTClassification code 10001499Term: Agitation mentalSystem Organ Class: 100000004873MedDRA version: 20.0Level: PTClassification code 10012271Term: Dementia Alzheimer's typeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-000799-39-NLAvanir Pharmaceuticals, Inc.750